Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 14th International Conference on Clinical & Experimental Cardiology Orlando, Florida, USA.

Day 1 :

OMICS International Cardiology 2016 International Conference Keynote Speaker Yoshiaki Omura photo
Biography:

Yoshiaki Omura received Oncological Residency training at Cancer Institute of Columbia University & Doctor of Science Degree through research on Pharmaco-Electro-Physiology of Single Cardiac Cells in-vivo and in-vitro from Columbia University. He researched EMF Resonance phenomenon at Graduate Experimental Physics Dept., Columbia University. He published over 270 original research articles, many chapters, & 9 books. He is currently Adjunct Prof. of Family & Community Medicine, NY Medical College; Director of Medical Research, Heart Disease Research Foundation of NY; President & Prof. of Int’l College of Acupuncture & Electro-Therapeutics, NY; Editor in Chief, Acupuncture & Electro-Therapeutics Research, Int’l Journal of Integrative Medicine, (indexed by 17 major int’l Indexing Periodicals); Editor of Integrative Oncology. Formerly, he was also Adjunct Prof. or Visiting Prof. in Universities in USA, France, Italy, Japan, Korea, China, etc.

Abstract:

Various cancers existing at various parts of the body were detected from rapidly changing QRS complex as well as slowly rising part of T-wave of every ECG by detecting maximum electromagnetic field (EMF) resonance phenomenon between 2 identical molecules with the same amount (the simple method of which received a US patent in 1993). Strong EMF resonance phenomenon between specific cancer’s microscope tissue were detected not only from rapidly changing part of QRS complex, but at specific part of slowly rising part of T-wave which corresponds to the “Vulnerable Period For Ventricular Fibrillation” where dV/dt is insignificantly small. We were also able to detect cancer of various organs including esophagus, stomach, pancreas, colon, lung, breast, uterus, ovary, prostate gland and common bone marrow related malignancies such as Hodgkin’s Lymphoma, non-Hodgkin’s Lymphoma, multiple Myeloma as well as four major categories of Leukemia. We were also able to find coexisting multiple cancers. From both QRS complex and rising part of T-wave, most of the drugs patients are taking 10 hours before taking ECG can also be detected. At Borrelia Burgdorferi (B.B.) Spirochete infected part of ECGs, we found significant decrease of Taurine and marked increase of ANP and Cardiac Troponin I and they are often associated with Atrial Fibrillation (A.F.). At every cancer tissue, hippocampus of patient with memory problems, & atrial fibrillation with significant B.B. infection, which is often unrecognized, Taurine was markedly reduced. Our research indicated B.B. infection is one of the major unrecognized causes of A.F. Optimal dose of Taurine of about 175mg made significant improvement to all these problems by improving circulation and increasing urinary excretion of bacteria, virus, fungus, and toxic substances. This new concept and method can be applied to any recorded ECGs for detection and screening of various cancers and infection including Lyme disease. Thus ECG can provide not only information on the heart, but also information on any single or multiple cancers, which exists at any part of the body.

OMICS International Cardiology 2016 International Conference Keynote Speaker Charles H Hennekens photo
Biography:

Hennekens is the first Sir Richard Doll Professor and Senior Academic Advisor to the Dean. He was first John Snow and first Eugene Braunwald Professor of Medicine at Harvard Medical School and first Chief of Preventive Medicine at Brigham and Women’s Hospital. His 173 H-index ranks him #14 Top Scientist in World. He was 3rd most widely cited medical researcher in world and 5 of top 20 were former trainees. He is #81 in world history for saving 1.1 million lives. He is a Fellow of the American College of Preventive Medicine (FACPM) and the American College of Cardiology (FACC).

Abstract:

Cardiovascular disease (CVD) is and will remain the leading avoidable cause of premature deaths in the US and is rapidly becoming so worldwide. The totality of available evidence on statins in the treatment and prevention of CVD is robust and includes over 200,000 randomized subjects from dozens of large scale trials designed a priori to test the hypothesis and their meta-analyses.  In secondary and high-risk primary prevention, clinicians should more widely prescribe evidence based doses of statins as first line drugs.  In low-risk primary prevention subjects previously considered ineligible, statins also have a favorable benefit to risk ratio.  Statins should be adjuncts, not alternatives to therapeutic lifestyle changes  of proven benefit including weight loss, physical activity, avoidance or cessation of cigarettes and diet.  In addition, any decision to prescribe statins should be based on individual clinical judgments that include all the risk factors of an individual and not simply those in any risk algorithm. Further, for individuals optimally treated with a statin and the responsible clinician wishes to prescribe additional therapy, the data are far less persuasive die nicotinic acid, omega-3 fatty acids, fibrates and ezetimibe. Finally, new and novel therapies, even if eventually proven to have a favorable benefit to risk ratio, will generally be adjuncts not alternatives to statins. The utilization of guidelines as guidance for clinicians should lead to more widespread and judicious prescription of evidence based doses of statins which, in turn, will lead to even greater net clinical and public health benefits in the treatment and prevention of CVD.